Overview

Establishing and Eliminating Cue-drug Associations in Human Cocaine Addiction

Status:
Terminated
Trial end date:
2019-12-01
Target enrollment:
0
Participant gender:
All
Summary
We will develop a procedure for conditioning cue-cocaine associations in human drug users. Next, we will reactivate that learning and intervene pharmacologically to prevent the reconsolidation of cue-drug memories. We hypothesize that a combined behavioral and pharmacological approach will have significant potential for persistently inhibiting relapse.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Yale University
Treatments:
Cocaine
Propranolol
Criteria
Inclusion Criteria:

1. Age 18 - 50 years

2. voluntary, written, informed consent

3. physically healthy by medical history, physical, neurological, ECG, and laboratory
examinations

4. DSM-IV criteria for Cocaine Abuse (305.60) or Cocaine Dependence (304.20)

5. recent street cocaine use in excess of that administered in the current study

6. intravenous and/or smoked (crack/freebase) use

7. positive urine toxicology screen for cocaine

8. for females, non-lactating, no longer of child-bearing potential (or agree to practice
effective contraception during the study), and a negative serum pregnancy (-HCG) test

9. able to read English and complete study evaluations.

Exclusion Criteria:

1. Other drug dependence (except nicotine)

2. a primary major DSM-IV psychiatric diagnosis (schizophrenia, bipolar disorder, etc.),
unrelated to cocaine

3. a history of significant medical (cardiovascular) or neurological illness (e.g., prior
myocardial infarction, current active symptoms of cardiovascular disease / angina,
evidence of cocaine-related cardiovascular symptoms, prior arrythmias of clinical
significance, and/or need for cardiovascular resuscitation, neurovascular events such
as transient ischemic attacks, stroke, and/or seizures)

4. current use of psychotropic and/or potentially psychoactive prescription medication

5. seeking treatment for drug abuse/dependence

6. those having contraindications to beta-blocker administration, including diagnoses of
asthma, bronchitis, emphysema, or a history of adverse reactions to beta-blockers
(including propranolol), as well as those with bradycardia and/or first-degree or
greater heart block by ECG